Piromelatine
- Generic Name
- Piromelatine
- Drug Type
- Small Molecule
- Chemical Formula
- C17H16N2O4
- CAS Number
- 946846-83-9
- Unique Ingredient Identifier
- S3UN2146K9
- Background
Piromelatine has been used in trials studying the treatment of Alzheimer's Disease.
Alzheimer's Disease Pipeline Shows Promise with 120+ Therapies in Development
• Over 120 Alzheimer's Disease treatment therapies are under development by 110+ companies globally, ranging from preclinical to marketed phases.
• Emerging therapies like NRDN-201, ST-501, and KarXT are in various clinical trial phases, showing potential for significant market impact.
• MapLight Therapeutics initiated a Phase 1 trial for ML-007/PAC, targeting schizophrenia and Alzheimer's disease psychosis, with Phase 2 trials planned.
• The FDA granted conventional approval to Leqembi (lecanemab-irmb), marking the first amyloid beta-directed antibody to transition from accelerated approval.
Alzheimer's Disease: Late-Stage Pipeline Explores Novel Therapeutic Targets Beyond Amyloid and Tau
• The Alzheimer's disease therapeutic pipeline is expanding beyond amyloid and tau targets, with 32 therapeutics in 48 Phase III trials exploring neuroprotection, neurotransmitters, and inflammation.
• Recent approvals of anti-amyloid antibodies like Leqembi and Kisunla have shown modest clinical benefits but also carry risks, prompting the development of alternative approaches.
• Several Phase III candidates, such as Athira's fosgonimeton, Anavex's ANAVEX 2-73, and Novo Nordisk's semaglutide, target different mechanisms like neurotrophic factors, neuronal homeostasis, and neuroinflammation.
• Experts suggest that combination therapies and brain-healthy lifestyles may be essential for effectively managing the heterogeneous nature of Alzheimer's disease.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath